CW MEDICINES LTD

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +5.8%

  £32,577,000 → £34,456,000

  highest in 3 filed years

• Cash

  +27.2%

  £858,000 → £1,091,000

• Net assets

  +2%

  £3,142,000 → £3,204,000

• Employees

  -23.5%

  34 → 26

• Operating profit

  +171.3%

  -£87,000 → £62,000

  first positive since 2024

• Profit before tax

  +171.3%

  -£87,000 → £62,000

  first positive since 2024

• Wages

  -9.8%

  £835,000 → £753,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Deloitte LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors have made an assessment of the Company's ability to continue as a going concern, which covers the period of more than 12 months from the data of approval of these financial statements. Based on this assessment, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, the company management continue to adopt the going concern basis in preparing the financial statements. The financial statements have been prepared using the going concern basis of accounting. The company is in a licencing contract with the parent undertaker (the Trust) for the duration of 5 years until 3rd April 2027. There is no indication or intention from either party to withdraw from this contract. The Company is forecast to be profitable in the forthcoming year, with a budgeted operating profit of £100k for 2025/26. A similar level of profitability is anticipated for 2026/27 in the original 5 years business case, and it's still deemed to be appropriate. As a wholly owned subsidiary, the Company benefits from the financial and operational support of the Trust. The Company has a positive cash balance of £1,091k at end of the year, the Directors are expected to meet the liabilities when due. Therefore, the directors at the time of approval of the financial statements believes going concern is the appropriate basis on which to prepare these accounts.”

Significant events

• “The ability to meet its working capital requirements. This is mitigated through a series of robust controls and processes to manage the working capital cycle and manage the cash flow on a day to day basis.”
• “Staffing resource and the ability to recruit/ retain appropriate levels of skilled workforce. This is mitigated through successful planning, retention plans, Personal Development Plans and career pathways and health & wellbeing staff offers.”
• “Patient experience and failure to deliver an appropriate quality of services. This is mitigated through improved staffing resilience, use of automated collection and close monitoring of waiting times, and capture real-time patient feedback via the accessible QR code system to ensure we can swiftly act on insights to elevate the overall patient experience.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.